![Geron Corp](/common/images/company/N_GERN.png)
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Show more
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the...
Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -2.13219616205 | 4.69 | 5.06 | 4.59 | 8151170 | 4.8261639 | CS |
4 | -0.06 | -1.29032258065 | 4.65 | 5.06 | 4.16 | 8111133 | 4.62017045 | CS |
12 | 0.71 | 18.2989690722 | 3.88 | 5.34 | 3.23 | 11557451 | 4.3638923 | CS |
26 | 2.68 | 140.314136126 | 1.91 | 5.34 | 1.64 | 11983498 | 3.44380995 | CS |
52 | 1.52 | 49.5114006515 | 3.07 | 5.34 | 1.64 | 8683365 | 3.04632132 | CS |
156 | 3.26 | 245.112781955 | 1.33 | 5.34 | 0.9899 | 5565704 | 2.71264552 | CS |
260 | 3.37 | 276.229508197 | 1.22 | 5.34 | 0.75 | 4599704 | 2.42802737 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.